$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

$gthp Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000147793222003472 Filed on May 16, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q1
Revenue	$5.000K	$5.000K	$0.00
YoY Change	150.0%
Cost Of Revenue	$1.000K	$1.000K	$0.00
YoY Change
Gross Profit	$4.000K	$4.000K	$0.00
YoY Change	100.0%
Gross Profit Margin	80.0%	80.0%
Selling, General & Admin	$712.0K	$426.0K	$807.0K
YoY Change	31.12%	-47.21%	270.18%
% of Gross Profit	17800.0%	10650.0%
Research & Development	$9.000K	$21.00K	$16.00K
YoY Change	-55.0%	31.25%	-33.33%
% of Gross Profit	225.0%	525.0%
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit	0.0%	0.0%
Operating Expenses	$721.0K	$447.0K	$823.0K
YoY Change	28.06%	-45.69%	240.08%
Operating Profit	-$717.0K	-$443.0K	-$823.0K
YoY Change	27.81%	-46.17%	240.08%
Interest Expense	$256.0K	$101.0K	$141.0K
YoY Change	-18.73%	-28.37%	-95.21%
% of Operating Profit
Other Income/Expense, Net	-$209.0K	$2.000K	$0.00
YoY Change	-55.81%		-100.0%
Pretax Income	-$926.0K	-$507.0K	-$517.0K
YoY Change	-10.44%	-1.93%	-118.95%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$926.0K	-$507.0K	-$517.0K
YoY Change	-10.44%	-1.93%	-118.95%
Net Earnings / Revenue	-18520.0%	-10140.0%
Basic Earnings Per Share	-$0.04	-$0.05	-$0.04
Diluted Earnings Per Share	-$0.04	-$0.05	-$0.04
COMMON SHARES
Basic Shares Outstanding	27.57M shares
Diluted Shares Outstanding	26.34M shares	20.68M shares	13.17M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$446.0K	$725.0K	$1.247M
YoY Change	-51.63%	-41.86%	5838.1%
Cash & Equivalents	$446.0K	$725.0K	$1.247M
Short-Term Investments
Other Short-Term Assets	$59.00K	$453.0K	$39.00K
YoY Change	-3.28%	1061.54%	8.33%
Inventory	$569.0K	$570.0K	$606.0K
Prepaid Expenses
Receivables	$29.00K	$39.00K	$24.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.103M	$1.787M	$1.916M
YoY Change	-32.74%	-6.73%	705.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.00K	$28.00K	$428.0K
YoY Change	542.86%	-93.46%	292.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.00K	$17.00K	$18.00K
YoY Change	0.0%	-5.56%	5.88%
Total Long-Term Assets	$400.0K	$400.0K	$446.0K
YoY Change	-6.32%	-10.31%	253.97%
TOTAL ASSETS
Total Short-Term Assets	$1.103M	$1.787M	$1.916M
Total Long-Term Assets	$400.0K	$400.0K	$446.0K
Total Assets	$1.503M	$2.187M	$2.362M
YoY Change	-27.29%	-7.41%	548.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.404M	$2.556M	$2.564M
YoY Change	0.88%	-0.31%	-13.55%
Accrued Expenses	$1.206M	$999.0K	$4.697M
YoY Change	-30.33%	-78.73%	55.17%
Deferred Revenue
YoY Change
Short-Term Debt	$378.0K	$788.0K	$1.296M
YoY Change	-65.42%	-39.2%	159.72%
Long-Term Debt Due	$47.00K	$67.00K	$245.0K
YoY Change	95.83%	-72.65%	-90.68%
Total Short-Term Liabilities	$5.996M	$5.449M	$9.229M
YoY Change	5.73%	-40.96%	0.07%
LONG-TERM LIABILITIES
Long-Term Debt	$986.0K	$1.420M	$579.0K
YoY Change	-26.09%	145.25%	-14.73%
Other Long-Term Liabilities	$287.0K	$307.0K	$489.0K
YoY Change	-25.65%	-37.22%	-72.94%
Total Long-Term Liabilities	$1.273M	$1.727M	$1.068M
YoY Change	-25.99%	61.7%	-57.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.996M	$5.449M	$9.229M
Total Long-Term Liabilities	$1.273M	$1.727M	$1.068M
Total Liabilities	$7.269M	$7.176M	$10.30M
YoY Change	-1.65%	-30.31%	-12.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$144.4M	-$143.4M
YoY Change	1.85%
Common Stock	$3.416M	$3.410M
YoY Change	0.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$132.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.766M	-$4.988M	-$7.992M
YoY Change
Total Liabilities & Shareholders Equity	$1.503M	$2.187M	$2.362M
YoY Change	-27.29%	-7.41%	548.9%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$926.0K	-$507.0K	-$517.0K
YoY Change	-10.44%	-1.93%	-118.95%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$349.0K	-$179.0K	-$320.0K
YoY Change	-73.46%	-44.06%	-39.62%
INVESTING ACTIVITIES
Capital Expenditures	-$17.00K	$14.00K	$1.000K
YoY Change	325.0%	1300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$17.00K	-$14.00K	-$1.000K
YoY Change	325.0%	1300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	87.00K	$275.0K	$1.386M
YoY Change	-91.25%	-80.16%	-498.28%
NET CHANGE
Cash From Operating Activities	-349.0K	-$179.0K	-$320.0K
Cash From Investing Activities	-17.00K	-$14.00K	-$1.000K
Cash From Financing Activities	87.00K	$275.0K	$1.386M
Net Change In Cash	-279.0K	$82.00K	$1.065M
YoY Change	-14.15%	-92.3%	-221.3%
FREE CASH FLOW
Cash From Operating Activities	-$349.0K	-$179.0K	-$320.0K
Capital Expenditures	-$17.00K	$14.00K	$1.000K
Free Cash Flow	-$332.0K	-$193.0K	-$321.0K
YoY Change	-74.68%	-39.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	785000	USD
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	514000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	70000	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	67000	USD
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	27000	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2022Q1	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	12000	USD
CY2022Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	31000	USD
CY2022Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	126000	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27568698	shares
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	41000	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	87000	USD
CY2022Q1	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	0	USD
CY2021Q1	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	448000	USD
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	40000	USD
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	161000	USD
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	745000	USD
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	736000	USD
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	38000	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5449000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	307000	USD
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2022Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	852000	USD
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	820000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	22000	USD
CY2022Q1	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	568000	USD
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1727000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	7176000	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22316000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13673000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	3410000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3403000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129042000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126800000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143442000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4989000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5445000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2187000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2040000	USD
CY2022Q1	us-gaap	Revenues Revenues	5000	USD
CY2021Q1	us-gaap	Revenues Revenues	0	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	4000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	0	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	40000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	36000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	386000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	771000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	447000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	823000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-443000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-823000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	101000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	141000	USD
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-6000	USD
CY2021Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-88000	USD
CY2022Q1	us-gaap	Other Expenses OtherExpenses	2000	USD
CY2021Q1	us-gaap	Other Expenses OtherExpenses	0	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-64000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	306000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-507000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-517000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-507000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-517000	USD
CY2022Q1	gthp	Preferred Stock Dividends PreferredStockDividends	-548000	USD
CY2021Q1	gthp	Preferred Stock Dividends PreferredStockDividends	-55000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1055000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-572000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	20683000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	13172000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20683000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13172000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5445000	USD
CY2022Q1	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	716000	USD
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	15000	USD
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	8000	USD
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Shares1 IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsShares1	105000	shares
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Shares IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsShares	64000	shares
CY2022Q1	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	81000	USD
CY2022Q1	gthp	Issuance Of Common Stock For Series F And Series F2 One Time Dividends IssuanceOfCommonStockForSeriesFAndSeriesF2OneTimeDividends	399000	USD
CY2022Q1	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	79000	USD
CY2022Q1	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-548000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-507000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4989000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-10855000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-507000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-517000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	41000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	64000	USD
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
CY2021Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62000	USD
CY2022Q1	gthp	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	0	USD
CY2021Q1	gthp	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	-448000	USD
CY2022Q1	gthp	Change In Fair Value Of Derivatives ChangeInFairValueOfDerivatives	6000	USD
CY2021Q1	gthp	Change In Fair Value Of Derivatives ChangeInFairValueOfDerivatives	88000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	16000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2022Q1	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	79000	USD
CY2021Q1	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	398000	USD
CY2022Q1	gthp	Gain From Forgiveness Of Debt GainFromForgivenessOfDebt	-41000	USD
CY2021Q1	gthp	Gain From Forgiveness Of Debt GainFromForgivenessOfDebt	-87000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	6000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-76000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	46000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-18000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	84000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	65000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-15000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	177000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-179000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-320000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	USD
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	365000	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2022Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-90000	USD
CY2021Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-557000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1818000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	125000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	275000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	82000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	643000	USD
CY2022Q1	us-gaap	Interest Paid InterestPaid	6000	USD
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	548000	USD
CY2021Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	55000	USD
CY2022Q1	gthp	Common Stock Issued For Payment Of Interest CommonStockIssuedForPaymentOfInterest	81000	USD
CY2022Q1	gthp	Issuance Of Series F2 Preferred Stock IssuanceOfSeriesF2PreferredStock	0	USD
CY2021Q1	gthp	Issuance Of Series F2 Preferred Stock IssuanceOfSeriesF2PreferredStock	2559000	USD
CY2022Q1	gthp	Issuance Of Warrants To Finders In Connection With Series F And Series F2 Preferred Stock IssuanceOfWarrantsToFindersInConnectionWithSeriesFAndSeriesF2PreferredStock	0	USD
CY2021Q1	gthp	Issuance Of Warrants To Finders In Connection With Series F And Series F2 Preferred Stock IssuanceOfWarrantsToFindersInConnectionWithSeriesFAndSeriesF2PreferredStock	151000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	592000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	14000	USD
CY2021Q1	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	1755000	USD
CY2021Q1	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	0	USD
CY2022Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. </strong><strong>ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2021, the Board simultaneously approved a 1-for-20 reverse stock split of our common stock and decreased the total number of authorized common shares to 500,000,000. On November 18, 2021, the Company submitted an Issuer Company Related Action Notification regarding the reverse stock split to the Financial Industry Regulatory Authority (“FINRA”). FINRA has not yet declared an effective date for the reverse stock split. The Company will adjust the number of shares available for future grant under its equity incentive plan and employee stock purchase plans and will also adjust the number of outstanding awards issued to reflect the effects of its reverse split. All historical share and per share amounts reflected throughout this report will be adjusted to reflect stock split at the time it becomes effective.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis of Presentation </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2021 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of March 31, 2022 and December 31, 2021, and the consolidated results of operations and cash flows for the three-month periods ended March 31, 2022 and 2021 have been included. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of March 31, 2022, it had an accumulated deficit of approximately $143.4 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision makers are the Chief Executive Officer and its Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At March 31, 2022, the Company had a negative working capital of approximately $3.7 million, accumulated deficit of $143.4 million, and incurred a net loss including preferred dividends of $1.1 million for the three months then ended. Stockholders’ deficit totaled approximately $5.0 million at March 31, 2022, primarily due to recurring net losses from operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three-month period ended March 31, 2022, the Company raised $0.4 million of proceeds from warrant exercises. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had warrants exercisable for approximately 25.4 million shares of its common stock outstanding at March 31, 2022, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in-the-money warrants would generate a total of approximately $4.7 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.</p>
CY2021Q4	gthp	Decrease In Authorized Common Share DecreaseInAuthorizedCommonShare	500000000	shares
CY2022Q1	gthp	Working Capital WorkingCapital	-3700000	USD
CY2022Q1	gthp	Accumulated Deficit AccumulatedDeficit	-143400000	USD
CY2022Q1	gthp	Net Loss Including Preferred Dividend NetLossIncludingPreferredDividend	1100000	USD
CY2022Q1	gthp	Total Stockholders Deficits TotalStockholdersDeficits	-5000000.0	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	400000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.</p>
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.</p>
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1254000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1255000	USD
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	69000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	69000	USD
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	32000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	32000	USD
CY2022Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	785000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	785000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	570000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	571000	USD
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	232000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	98000	USD
CY2021Q4	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	351000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1775000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1761000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1747000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1747000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14000	USD
CY2022Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	573000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	621000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	41000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	261000	USD
CY2022Q1	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	42000	USD
CY2021Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	39000	USD
CY2022Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	299000	USD
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	349000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	41000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	49000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1228000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1768000	USD
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	514000000	USD
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	337000000	USD
CY2022Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	165000000	USD
CY2021Q4	gthp	Accounts Receivable Net Of Allowance AccountsReceivableNetOfAllowance	126000000	USD
CY2022Q1	us-gaap	Notes Payable NotesPayable	39000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	172000000	USD
CY2022Q1	gthp	Accounts Receivable Net Of Allowance AccountsReceivableNetOfAllowance	126000000	USD
CY2021Q4	us-gaap	Notes Payable NotesPayable	46000	USD
CY2022Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	61600000	USD
CY2022Q1	gthp	Warrants Warrants	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.</p>
CY2022Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	400000	USD
CY2021Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	-38000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	-32000	USD
CY2022Q1	gthp	Summary Of Changes To Level3 Instruments SummaryOfChangesToLevel3Instruments	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(in thousands)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Senior Secured Debt</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Derivative</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance, December 31, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in fair value during the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance, March 31, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(38</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(38</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></tbody></table>
CY2022Q1	gthp	Common Stock Shares Authorized Shares CommonStockSharesAuthorizedShares	500000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	22316412	shares
CY2021Q4	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	13673583	shares
CY2022Q1	gthp	Schedule Common Stock Issued Table Textblock ScheduleCommonStockIssuedTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock warrants exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,477,923</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock for payment of Series D preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,109</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock for payment of Series E preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock for payment of Series F preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">158,662</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock for payment of Series F-2 preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,535</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock for payment of interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,262</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock for Series F one-time 15% dividend</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock for Series F-2 one-time 15% dividend</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">368,505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Conversion of Series E preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,070,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Conversion of Series F preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">60,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issued during the three months ended March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,642,829</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Summary table of common stock share transactions:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,673,583</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issued in 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,642,829</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">22,316,412</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q1	gthp	Common Stock Warrants Exercised CommonStockWarrantsExercised	4477923	shares
CY2022Q1	gthp	Stock Issued During Period Shares Issued For Series D Dividends StockIssuedDuringPeriodSharesIssuedForSeriesDDividends	23109	shares
CY2022Q1	gthp	Stock Issued During Period Shares Issued For Series F Dividends StockIssuedDuringPeriodSharesIssuedForSeriesFDividends	12432	shares
CY2022Q1	gthp	Stock Issued During Period Shares Issued For Series F2 Dividends StockIssuedDuringPeriodSharesIssuedForSeriesF2Dividends	95535	shares
CY2022Q1	gthp	Stock Issued During Period Shares Issued For Payment Of Interest StockIssuedDuringPeriodSharesIssuedForPaymentOfInterest	121262	shares
CY2022Q1	gthp	Stock Issued During Period Shares Issued For Series F One Time Dividend StockIssuedDuringPeriodSharesIssuedForSeriesFOneTimeDividend	255401	shares
CY2022Q1	gthp	Stock Issued During Period Shares Issued For Series F2 One Time Dividend StockIssuedDuringPeriodSharesIssuedForSeriesF2OneTimeDividend	368505	shares
CY2022Q1	gthp	Conversion Of Stock E Shares Issued1 ConversionOfStockESharesIssued1	3070000	shares
CY2022Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	60000	shares
CY2022Q1	gthp	Stock Issued During Period StockIssuedDuringPeriod	8642829	shares
CY2020	gthp	Shares Outstanding One SharesOutstandingOne	13673583	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	8642829	shares
CY2022Q1	gthp	Shares Outstanding One SharesOutstandingOne	22316412	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	27669634	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2284324	shares
CY2022Q1	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice	0.16
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	25385310	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.30
CY2022Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.10	pure
CY2022Q1	gthp	Outstanding End OutstandingEnd	1500000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.49
CY2022Q1	gthp	Weighted Average Remaining Contractual Life Outstanding WeightedAverageRemainingContractualLifeOutstanding	P8Y3M18D
CY2022Q1	gthp	Agrregate Intrensic Value Outstanding AgrregateIntrensicValueOutstanding	240	USD
CY2022Q1	gthp	Number Of Shares Exercisable NumberOfSharesExercisable	1045227	shares
CY2022Q1	gthp	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Ending Balance SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceEndingBalance	0.49
CY2022Q1	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P8Y3M18D
CY2022Q1	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	167	USD
CY2022Q1	gthp	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	219558	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3M
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
CY2022Q1	gthp	Short Term Notes Payable ShortTermNotesPayable	43253	USD
CY2021Q4	gthp	Short Term Notes Payable ShortTermNotesPayable	87615	USD
CY2021Q1	gthp	Expected Term Years ExpectedTermYears	P10Y
CY2021Q1	gthp	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	1.5312	pure
CY2021Q1	gthp	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0098	pure
CY2021Q1	gthp	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0.0000	pure
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	355000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	377	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	82000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	112000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	115000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	118000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	50000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	477000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	100000	USD
CY2022Q1	gthp	Operating Lease Liability1 OperatingLeaseLiability1	377000	USD
CY2022Q1	gthp	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	P4Y2M12D
CY2022Q1	gthp	Weighted Average Discount Rateoperating Lease WeightedAverageDiscountRateoperatingLease	0.114	pure
CY2016Q2	gthp	Royalty Percent RoyaltyPercent	20
CY2016Q2	gthp	Licences Licences	1000000.0	USD
CY2016Q2	gthp	Sales sales	4000000.0	USD
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5000000	shares
CY2020Q1	gthp	Warrants Broken Into Four Tranches WarrantsBrokenIntoFourTranches	1250000	shares
CY2020Q1	us-gaap	Share Price SharePrice	0.25
CY2022Q1	gthp	Financing Agreement Amount FinancingAgreementAmount	1000000	USD
CY2019Q3	gthp	Consideration Received ConsiderationReceived	885144	USD
CY2019Q3	gthp	Escrow Agent Rate Per Share EscrowAgentRatePerShare	1.90
CY2022Q1	gthp	Annual Interest Rate Description One AnnualInterestRateDescriptionOne	The notes carry annual interest rates between 4.3% and 16%, or 18% in the event of default
CY2022Q1	gthp	Notes Payable In Default NotesPayableInDefault	43000	USD
CY2020Q4	gthp	Notes Payable In Default NotesPayableInDefault	88000	USD
CY2022Q1	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	400000	USD
CY2022Q1	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	74778	USD
CY2021Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	64778	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5211	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	13586	USD
CY2022Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	38129	USD
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	31889	USD
CY2022Q1	gthp	Future Debt Obligations FutureDebtObligations	594643	USD
CY2022Q1	gthp	Bond Payable Discount And Unamortized Debt Issuance Costs BondPayableDiscountAndUnamortizedDebtIssuanceCosts	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10% Senior Unsecured Convertible Debentures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Debt Issuance costs to be amortized</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(62</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(69</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Debt Discount</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(216</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(241</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Long-term convertible debt</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>852</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>820</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q1	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130	USD
CY2021Q4	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130	USD
CY2022Q1	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-62	USD
CY2021Q4	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-69	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	216	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	241	USD
CY2022Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	852	USD
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	820	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1055000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-572000	USD
CY2022Q1	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	20683	shares
CY2021Q1	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	13172	shares
CY2022Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.05
CY2021Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.04
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20683	shares
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13172	shares
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32116	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35709	shares
CY2022Q1	gthp	Decrease Net Income Loss DecreaseNetIncomeLoss	41232	USD
CY2022Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	41232	USD
CY2021Q1	gthp	Troubled Debt Restructuring Description TroubledDebtRestructuringDescription	the troubled debt restructurings in total would have decreased the net loss by $972,000, causing the per share calculation to change from .04 to .11 net loss per share
CY2021Q1	gthp	Decrease Net Income Loss DecreaseNetIncomeLoss	972000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	650000	shares

Files In Submission

Name	View Source	Status
0001477932-22-003472-index-headers.html	Edgar Link	pending
0001477932-22-003472-index.html	Edgar Link	pending
0001477932-22-003472.txt	Edgar Link	pending
0001477932-22-003472-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gthp-20220331.xsd	Edgar Link	pending
gthp-20220331_cal.xml	Edgar Link	unprocessable
gthp-20220331_def.xml	Edgar Link	unprocessable
gthp-20220331_lab.xml	Edgar Link	unprocessable
gthp-20220331_pre.xml	Edgar Link	unprocessable
gthp_10q.htm	Edgar Link	pending
gthp_10q_htm.xml	Edgar Link	completed
gthp_ex311.htm	Edgar Link	pending
gthp_ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

2022 Q2 Form 10-Q Financial Statement

#000147793222003472 Filed on May 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP GUIDED THERAPEUTICS INC Stock $gthp

2022 Q2 Form 10-Q Financial Statement

#000147793222003472 Filed on May 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp